DCFPyL F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
DCFPyL F-18
Accession Number
DB14805
Type
Small Molecule
Groups
Investigational
Description

DCFPyL F-18 is under investigation in clinical trial NCT02691169 (Integrated 18F-labelled PSMA Project).

Structure
Thumb
Synonyms
  • 18F-DCFPYL
Categories
Not Available
UNII
3934EF02T7
CAS number
1207181-29-0
Weight
Average: 441.403
Monoisotopic: 441.152526384
Chemical Formula
C18H23FN4O8
InChI Key
OLWVRJUNLXQDSP-MVBOSPHXSA-N
InChI
InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1
IUPAC Name
(2S)-2-({[(1S)-1-carboxy-5-{[6-(¹⁸F)fluoropyridin-3-yl]formamido}pentyl]carbamoyl}amino)pentanedioic acid
SMILES
OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
32702072

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingDiagnosticProstate Cancer1
0RecruitingDiagnosticProstate Cancer1
1Active Not RecruitingDiagnosticMetastatic Hormone Refractory Prostate Cancer2
1RecruitingDiagnosticNeoplasms Malignant / Schwannomas1
1RecruitingDiagnosticProstate Cancer2
1RecruitingTreatmentProsatatic Neoplasm / Prostate Cancer1
2Not Yet RecruitingDiagnosticProstate Cancer1
2RecruitingDiagnosticMetastatic Hormone Refractory Prostate Cancer / Prostate Cancer / Prostate Neoplasms / Prostatic Neoplasms2
2RecruitingDiagnosticProstate Cancer1
2RecruitingScreeningCastrate Sensitive Prostate Cancer1
2, 3CompletedDiagnosticProstate Cancer1
2, 3RecruitingDiagnosticProstate Cancer1
2, 3RecruitingDiagnosticProstate Cancer Adenocarcinoma1
3RecruitingDiagnosticAdenocarcinoma, Prostate / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer1
Not AvailableActive Not RecruitingDiagnosticAdenocarcinoma of the Prostate1
Not AvailableActive Not RecruitingDiagnosticRenal Cancers / Renal Cell Adenocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.191 mg/mLALOGPS
logP-0.37ALOGPS
logP-0.32ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)2.99ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area195.02 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity101.38 m3·mol-1ChemAxon
Polarizability42 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:28 / Updated on May 21, 2019 12:29